BROSSARD, Quebec, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSXV:ADK, OTCQB:DGNOF, FWB: 4D4A)), a pioneer in applying techniques in Artificial Intelligence (AI) for the early detection of eye-related health issues, is pleased to provide an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025.The Corporation continues to execute its strategy to secure approvals in three targeted jurisdict
Within healthcare and life sciences, particularly in ophthalmology and medical imaging, this article demonstrates the increasing acceptance of AI as a valuable diagnostic tool. This trend will likely drive further investment and innovation in AI-powered diagnostic solutions, potentially leading to improved patient outcomes and more efficient healthcare delivery. Furthermore, the regulatory successes of CARA can provide a model for other AI healthcare applications.
For healthcare providers, CARA's potential approval means access to an AI-powered diagnostic tool that could improve the efficiency and accuracy of eye disease detection, leading to earlier intervention and better patient outcomes. This will impact training, integration into existing workflows, and reliance on automation for diagnosis.